Analysts Set Integer Holdings Co. (NYSE:ITGR) Target Price at $145.44

Shares of Integer Holdings Co. (NYSE:ITGR) have earned a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $145.44.

Several research analysts recently commented on the stock. Truist Financial lifted their target price on shares of Integer from $147.00 to $163.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Piper Sandler restated an “overweight” rating and issued a $140.00 price objective (up previously from $125.00) on shares of Integer in a research report on Friday, October 25th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Integer in a research note on Tuesday, December 3rd. Citigroup raised their target price on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research note on Wednesday, December 11th. Finally, Bank of America upped their price target on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st.

Integer Stock Performance

NYSE ITGR opened at $134.76 on Friday. The company has a 50-day simple moving average of $134.70 and a two-hundred day simple moving average of $126.81. Integer has a 12-month low of $94.56 and a 12-month high of $142.76. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of 41.59, a PEG ratio of 2.02 and a beta of 1.12. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67.

Integer (NYSE:ITGR) last issued its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.07. The company had revenue of $431.42 million during the quarter, compared to analysts’ expectations of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. Integer’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.27 EPS. On average, equities analysts forecast that Integer will post 5.33 EPS for the current year.

Institutional Investors Weigh In On Integer

Several hedge funds have recently made changes to their positions in the company. Loomis Sayles & Co. L P grew its holdings in Integer by 3.0% in the third quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider’s stock worth $69,943,000 after purchasing an additional 15,446 shares during the period. Jane Street Group LLC raised its stake in Integer by 23.3% during the third quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock valued at $19,682,000 after buying an additional 28,572 shares during the last quarter. Earnest Partners LLC boosted its holdings in Integer by 3.2% in the second quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock worth $139,911,000 after acquiring an additional 37,340 shares in the last quarter. Verition Fund Management LLC grew its stake in shares of Integer by 17.4% in the third quarter. Verition Fund Management LLC now owns 3,470 shares of the medical equipment provider’s stock worth $451,000 after acquiring an additional 515 shares during the last quarter. Finally, Great Lakes Advisors LLC raised its position in shares of Integer by 56.7% in the 2nd quarter. Great Lakes Advisors LLC now owns 45,218 shares of the medical equipment provider’s stock worth $5,236,000 after purchasing an additional 16,355 shares during the last quarter. 99.29% of the stock is currently owned by institutional investors.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.